An OMRF discovery could potentially open the door for the first drug option to treat age-related muscle weakness and atrophy.
In 1968, doctors told Greg Kindell that he had acute myeloid leukemia and he had just six weeks to live. Now he’s been cancer-free for 50 years.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
The project will focus on comparing certain immune cells in patients with Sjögren’s to those of healthy controls.
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
For Mary Long, the answer to her pain may, literally, be right around the corner.